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Background: Crohn’s disease (CD) and Hidradenitis suppurativa (HS) are both chronic inflammatory diseases. The
pathogenesis of these diseases is multifactorial, due to the interaction of genetic and environmental factors leading to a
deregulated local immune response where T lymphocytes play a major role. To the best of our knowledge, no previous
study has clarified whether the pathogenetic mechanism of perianal CD and HS is the same. We therefore analyzed the
cellular expression pattern and the cytokine repertoire in three patients suffering from both perianal CD and HS.
Methods: We evaluated three patients affected by concurrent HS and CD with fistulizing perianal disease. Surgical
specimens have been fixed and embedded in paraffin prior to sectioning for histological examination. Inflammatory
tissue curettages have been recovered during intervention from perianal fistulas and HS lesions in order to analyze the
phenotypic and functional characteristics of infiltrating T cells. In particular we evaluated T cells, by flow cytometry, for
cytokine production profile and expression of surface markers. Moreover, analysis of the T cell repertoire was performed
by means of spectratyping, in only one patient.
Results: A higher frequency of CD4+ CD161+ T lymphocytes has been detected in CD fistulas and in HS lesions than in
peripheral blood (PB) samples. In the patient in whom we derived enough cells from the three sources, we found
higher frequency of CD4+ IL-17- producing cells in HS lesion and fistula lesion compared to PB. It is noteworthy that
the same clonotypes were expanded in this patient in T cells derived from both HS lesion and fistula lesion.
Conclusion: The presence of numerous CD4+ CD161+ lymphocytes in fistula and HS lesion curettages suggests that
these cells may play a pathogenic role, and candidates CD161 as a possible biological target for medical treatment.
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Crohn’s disease (CD) and hidradenitis suppurativa (HS)
are chronic inflammatory diseases. HS involves the hair
follicles in apocrine glandular zones, affecting the axillae,
groins, external genitals or perianal regions. It is charac-
terized by recurrent, spontaneously draining, suppura-
tive lesions and long-lasting subcutaneous sinus tracts,
cutaneous fistulae or dermal-cutaneous scars [1].
The prevalence of HS is approximately 1 in 300 and typ-
ically commences during puberty and the teenage years,* Correspondence: francesco.tonelli@unifi.it
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unless otherwise stated.more frequently in females. Familial history is docu-
mented in a quarter of the patients with an autosomal in-
heritance [1].
CD may involve any part of the gastrointestinal tract and
is defined by the presence of discontinuous, transmural,
inflammatory lesions [2]. Abdominal pain and weight loss
are the typical presenting symptoms. CD can be divided
into three forms: inflammatory, fistulizing or obstructive.
Between 60% and 80% of CD patients suffer from perianal
fistulas [3,4]. Previous reports have suggested a possible
association between CD and HS (Table 1) [5-16].
Although smoking is regarded as a risk factor of both
CD and HS recurrence, the etiology of these diseases is
still largely unknown and is likely to be multifactorial. ItThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Association between CD and HS as reported in
the literature (HS-CD = diagnosis of HS predated that of
CD; CD-HS = diagnosis of CD predated that of HS)
Author Year N° patients Sex Sequence
LS Ostlere 1991 3 F,F,M CD-HS, CD-HS,
CD-HS
C Gower-Rousseau 1992 3 M CD-HS, CD-HS,
CD-HS
NP Burrows 1992 2 M,F HS-CD, HS-CD
RL Attanoos 1993 3 F,M,M CD-HS, HS-CD,
CD-HS
AA Kafity 1993 1 M CD-HS
JM Church 1993 61 Both Multiple
EV Tsianos 1995 1 M CD-HS
MK Roy 1997 1 M HS-CD
F Martinez 2001 1 F CD-HS
M Roussomoustakaki 2003 1 F HS-CD
HH Van der Zee 2009 102 Both Multiple
S Yazdanyar 2010 2 F,F HS-CD, HS-CD
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may cooperate in leading to a deregulated local immune
response where T lymphocytes play a major role [1,17].
CD4+ T helper (Th) cells can be divided into different
subsets according to their cytokine production profile:
Th1 cells produce interferon (IFN)-γ, thus protecting
against intracellular pathogens, Th2 cells produce inter-
leukins (IL)-4, IL-5, IL-9 and IL-13 and offer defence
against parasitic helminths, while Th17 cells produce IL-
17 and protect from fungal infections [18]. In addition
to their protective role against pathogens, Th lympho-
cytes also contribute to the development of immune-
mediated disorders: in particular both Th1 and Th17
cells have been credited to being involved in inducing
and maintaining an intestinal inflammatory reaction in
experimental animal models as well as in human CD
[18,19]. Furthermore, biological therapy targeting tumor
necrosis factor (TNF)-α with specific monoclonal anti-
bodies, has shown to be particularly effective in both CD
and HS treatment [1,6,17]. Recently, local injection of
anti-TNF-α antibodies (Ab) has proved to be a safe and
effective therapy for perianal fistulas in CD [4,20].
We recently observed three CD patients with perianal
fistulas and suffering from HS, who gave us the oppor-
tunity to compare the cellular and cytokine expression
profile of these lesions.
Methods
Between February and October 2011, we operated three
patients affected by concurrent HS and CD with fistuliz-
ing perianal disease. Surgical treatment consisted in re-
section of the HS lesion, followed by fistulotomy (n = 1)or fistulectomy (n = 2). Surgical specimens were fixed in
10% neutral buffered formalin and embedded in paraffin
prior to sectioning for histological examination. Inflam-
matory tissue curettages were recovered during inter-
vention from perianal fistulas and HS lesions in order to
analyze the phenotypic and functional characteristics of
the infiltrating T cells. These features were then com-
pared with those of peripheral blood T lymphocytes.
To isolate T lymphocytes, tissue fragments were mechan-
ically disrupted with a MEDI machine (Becton Dickinson).
Fluorochrome-conjugated mAbs and isotype-matched con-
trol mAbs were purchased from BD Biosciences (San Jose,
CA). The fluorochrome-conjugated anti-IL-17 mAbs was
obtained from eBioscience (San Diego, CA). PMA, iono-
mycin and brefeldin A were purchased from Sigma Chem-
ical Co. (St. Louis, MO). Mononuclear cells (MNCs) from
the different tissues were analyzed for intracellular
cytokine production as previously described [18]. All
procedures in the study are in accordance with the eth-
ical standards of the Regional Committee on Human
Experimentation.
Analysis of the T cell repertoire was performed by
means of spectratyping, a PCR-based technique which
allows to assess CDR3 region length in the TCR families.
The CDR3 region is unique for a given T cell and conse-
quently all cells bearing a particular CDR3 will belong to
that clone. Due to an allelic exclusion phenomenon, only
a TCR-BV gene is predictively rearranged in each T cell.
Therefore, according to TCR-BV gene, modification of
specific clonotypes can be monitored both in vivo and
in vitro. With this technique, a TCR family is graphically
described by a series of peaks with Gaussian distribution.
Alteration of intensity and/or distribution of the peaks
indicates a perturbation of the T cell repertoire. Ex-
tended peaks are directly sequenced in order to assess
the clonotype composition of each peak [21].
Results
The three patients were Caucasian females, two of them
were smokers. CD has been diagnosed at a mean age of
23 years and histologically confirmed in all patients. CD
was ileal in 2 patients and colic in one; it was stricturing
in all three. Perianal fistulas have occurred at a mean
age of 26.3 years. In two cases, the fistula was recurrent,
trans-sphincteric in two patients and anovaginal in one.
HS was diagnosed with a mean of 10.7 years after CD
diagnosis. All patients have been medically treated for
CD with cycles of steroids and mesalamine, whilst two
patients have been also treated with azatioprine and
infliximab for a mean of 7 and 8 months, respectively. In
all cases immunosuppressive treatment has been sus-
pended one month prior to surgery. The HS lesions
were LC1 and Hurley stage II [22,23] in all patients and
were localized at the axilla in 2 cases and at the right
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rizes clinical features of the recruited patients.
Histological examination reveals florid inflammatory
granulation tissue in perianal CD (Figure 1), and marked
inflammatory infiltrate in apocrine glands as well as ad-
jacent connective tissue in HS, the CD4+ T cells repre-
senting the predominant subtype in this latter (Figure 2).
MNCs have been isolated from peripheral blood (PB)
samples, fistula curettage and HS lesions, and analyzed
for surface marker expression and for the ability to pro-
duce IL-17 and IFN-γ after polyclonal stimulation. In
particular, due to the low number of cells recovered
from fistula curettage, analysis of surface markers and
intracellular cytokines was possible in all three patients
only on PB- and HS lesion-derived cells. The expression
of the Th1 associated molecule CXCR3 was significantly
lower in HS-derived CD4+ T lymphocytes than in the
PB-derived ones. On the contrary, the expression of the
Th17 associated molecule CD161 was significantly higher
in HS lesion-derived CD4+ T lymphocytes than in those
obtained from PB (Figure 3A). Accordingly, CD4+ T lym-
phocytes producing IFN-γ were more abundant in PB
than in HS lesions, whereas CD4+ T cells producing IL-17
were more abundant in HS lesions than in PB (Figure 3B
and C). In the only case in which we had the possibility to
analyze the three different sources (PB, HS lesion, and fis-
tula curretage), we found more CD4+ IL-17- producing
cells in HS lesion and fistula lesion than in PB, even if the
CD4+ IFN-γ - producing cells did not differ among the
different sources (Figure 3C). It is noteworthy that CD4+
T lymphocytes derived from PB, HS and fistula, in the
same patient, exhibited a similar TCRVB distribution sug-
gesting an expansion of the same clonotypes (Figure 3D).
After a follow-up of 24 months one patient had no evi-
dence of disease (patient number 3), whereas in the
remaining two patients the HS lesion recurred after 13.2Table 2 Clinical features of enrolled patients
Patient Sex/age
at surgery
(years)
Smoker Age at CD
diagnosis
(years)
Age at perianal
fistula diagnosis
(years)
C
t
f
1 F/49 Yes 21 20 Il
2 F/26 Yes 22 26 C
3 F/42 No 26 33 Il(patient number 1) and 16.4 months (patient number 2)
respectively.
Discussion
The primum movens of HS seems to be related to the
occlusion of the hair follicles by keratinous plugging
followed by their dilatation and disruption. Secondary
bacterial infection of the apocrine glands may result in
abscess formation, gland rupture, inflammation and fis-
tula forming. Long-standing HS in the anogenital region
has been suggested to precede squamous cell carcinoma
[24]. The present study describes the co-morbidity of
perianal CD and HS found in three patients. The associ-
ation between HS and CD has recently been reinforced
in nine case reports and two retrospective studies [5-16].
On interviewing 102 CD patients, Van der Zee et al.
found a history of recurrent painful boils in the axillae
and/or groins compatible with HS in 17% of cases [15].
Church et al. reviewed hospital records of 61 HS pa-
tients and observed that in 24 had also been diagnosed
for CD [10]. Anal localization of HS may clinically over-
lap perianal CD with suppurative complications leading
to misinterpretation. Noteworthy, HS can arise either
before or after CD. In the latest report, CD diagnosis
predated that of HS by an average of 3.5 years [10]. In
line with these data, in our patients the diagnosis of HS
followed that of CD.
Even if performed on a low number of patients, the
present study is the first to compare the inflammatory
scenario of both perianal CD fistulas and HS lesions. We
documented the accumulation of CD161+ T lympho-
cytes, that are well known to be enriched in the Th17,
Th17/Th1 and non classic Th1 phenotypes [20,21], in
the CD fistula and HS lesion curettages. Interestingly,
Th1 and Th17 lymphocytes have been claimed to play a
role in CD pathogenesis [25]. The coexistence of Th1D localization/
ype of perianal
istula
Age at HS
diagnosis
(years)
Type of HS Previous
therapy
eal/transsphincteric 33 Inguinal, recurrent Steroid
Mesalamine
Azatioprine
Infliximab
olic/Ano-vaginal 26 Axillary Steroid
Mesalamine
Adalimumab
eal/transsphincteric 40 Axillary Steroid
Mesalamine
Azatioprine
Infliximab
Figure 1 Perianal fistula sample: haematoxylin-eosin (H&E) staining reveals denuded surface, overlying florid inflammatory granulation tissue
(original magnification ×5). The CD3+, CD4+ and CD8+ T cells are identified by appropriate immunohistochemical stains (patient n°3).
Figure 2 HS sample: in HS, marked acute and chronic inflammatory infiltrate involves apocrine glands as well as adjacent connective tissue
(A: H&E, original magnification, ×5; B: H&E, original magnification, ×20) (patient n°3). Chronic inflammatory infiltrate includes T lymphocytes (CD3+)
with CD4+ T cells representing the predominant subtype (original magnification, ×20). (inferior panel: CD3, CD4, CD8).
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Figure 3 CD4+ CD161+ T cells producing IL-17 accumulate in HS lesion and gut. (A) CXCR3 and CD161 expression in CD4+ T lymphocytes
obtained from PB and HS lesion of the three patients with HS associated with CD. Symbols represents each single patient. *p < 0.05. (B) Cytokines
production profile of CD4+ T lymphocytes obtained from PB and HS lesions of the three patients with HS associated with CD. Symbols represents each
single patient. (C) Flow cytometric plots intracellular staining of IL-17 and IFN-γ cytokines of CD4+ T lymphocytes after in vitro polyclonal stimulation,
obtained from indicated tissues. One donor is represented. (D) Three representative TCR-BV families (TCR-BV3; TCR-BV5.1; TCR-BV22) in HS lesion zones,
blood and gut of one patient with HS associated to CD. Asterisks indicate the presence of clonotypes found expanded in the peaks of interest.
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cooperation in the pathogenesis of several inflammatory
diseases have also been reported [18,21]. It has also been
shown that Th17 cells can shift towards the Th1 pheno-
type in the presence of IL-12, through an intermediate
state in which the cells are capable of producing both
IL-17A and IFN-γ (Th17/Th1 subset) [18,21]. Since IL-
12 is highly expressed in CD tissue samples [25], we
speculate that Th17 cells could be modulated to become
Th17/Th1, or even Th1, during the course of the dis-
ease. Accordingly, it has recently been suggested that
Th1 and Th17 cytokines can act synergistically in the
development of the disease [25]. Indeed, some reports
describe the effectiveness of the anti-IL-12/23 p40 chain
monoclonal antibody ustekinumab, which inhibits receptor-
binding of both IL-12 and IL-23, thus blocking Th1 and
Th17 differentiation, in the treatment of CD [26]. More-
over it has been recently described the involvement ofIL-23/Th17 pathway in the pathogenesis of skin hidrade-
nitis suppurative [27].
The finding of a possible pathogenic association be-
tween CD and HS, could have also therapeutical implica-
tions. Indeed, treatment with biologics blocking TNF-α
has been observed in both diseases [13,14,17], and a
favourable outcome has been reported particularly in the
early stages of HS. However, refractory cases to anti-
TNF-α therapy have also been described as well as pa-
tients developing HS under anti-TNF-α treatment [28].
Finally, here we describe a possible association be-
tween CD and HS, based on immunological analysis of
infiltrating T cells compared to PB; in any case add-
itional factors could be involved in the pathogenesis of
the diseases and of course additional studies are neces-
sary to define if other molecules associated to these
disease will be common to both or specific of each
one [29-31].
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In conclusion, this work reinforces the link between HS
and CD, providing evidence that CD4+ CD161+ T lym-
phocytes accumulate in perianal fistulas and HS in CD
patients and may play a crucial role in the pathogenesis
of both diseases. Potential therapeutic implications of
these results need to be further investigated.
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